28th Mar 2006 12:00
GlaxoSmithKline PLC28 March 2006 Issued - 28 March 2006, London, UK GSK ANNOUNCES POSITIVE RESULTS OF SERETIDE SURVIVAL STUDY IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) GlaxoSmithKline plc announces preliminary results from the TORCH study (TOwardsa Revolution in COPD Health) which show a 17% relative reduction in mortalityover three years for patients receiving SeretideTM 50/500(micro)g (EU) /Advair(R) (US) (salmeterol/fluticasone propionate) as compared with patients onplacebo (p=0.052*). This is the first study to investigate the effects ofpharmacotherapy on all-cause mortality in patients with COPD. The primarycomparison was between Seretide/Advair and placebo. Seretide/Advair also reduced the rate of COPD exacerbations by 25% compared toplacebo (pRelated Shares:
Glaxosmithkline